Cargando…
An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients
Hepatitis C virus (HCV)-related cirrhosis leads to a heavy global burden of disease. Clinical risk stratification in HCV-related compensated cirrhosis remains a major challenge. Here, we aim to develop a signature comprised of immune-related genes to identify patients at high risk of progression and...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326446/ https://www.ncbi.nlm.nih.gov/pubmed/34350203 http://dx.doi.org/10.3389/fmed.2021.716869 |
_version_ | 1783731821072089088 |
---|---|
author | Guo, Cheng Dong, Chenglai Zhang, Junjie Wang, Rui Wang, Zhe Zhou, Jie Wang, Wei Ji, Bing Ma, Boyu Ge, Yanli Wang, Zhirong |
author_facet | Guo, Cheng Dong, Chenglai Zhang, Junjie Wang, Rui Wang, Zhe Zhou, Jie Wang, Wei Ji, Bing Ma, Boyu Ge, Yanli Wang, Zhirong |
author_sort | Guo, Cheng |
collection | PubMed |
description | Hepatitis C virus (HCV)-related cirrhosis leads to a heavy global burden of disease. Clinical risk stratification in HCV-related compensated cirrhosis remains a major challenge. Here, we aim to develop a signature comprised of immune-related genes to identify patients at high risk of progression and systematically analyze immune infiltration in HCV-related early-stage cirrhosis patients. Bioinformatics analysis was applied to identify immune-related genes and construct a prognostic signature in microarray data set. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted with the “clusterProfiler” R package. Besides, the single sample gene set enrichment analysis (ssGSEA) was used to quantify immune-related risk term abundance. The nomogram and calibrate were set up via the integration of the risk score and clinicopathological characteristics to assess the effectiveness of the prognostic signature. Finally, three genes were identified and were adopted to build an immune-related prognostic signature for HCV-related cirrhosis patients. The signature was proved to be an independent risk element for HCV-related cirrhosis patients. In addition, according to the time-dependent receiver operating characteristic (ROC) curves, nomogram, and calibration plot, the prognostic model could precisely forecast the survival rate at the first, fifth, and tenth year. Notably, functional enrichment analyses indicated that cytokine activity, chemokine activity, leukocyte migration and chemotaxis, chemokine signaling pathway and viral protein interaction with cytokine and cytokine receptor were involved in HCV-related cirrhosis progression. Moreover, ssGSEA analyses revealed fierce immune-inflammatory response mechanisms in HCV progress. Generally, our work developed a robust prognostic signature that can accurately predict the overall survival, Child-Pugh class progression, hepatic decompensation, and hepatocellular carcinoma (HCC) for HCV-related early-stage cirrhosis patients. Functional enrichment and further immune infiltration analyses systematically elucidated potential immune response mechanisms. |
format | Online Article Text |
id | pubmed-8326446 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83264462021-08-03 An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients Guo, Cheng Dong, Chenglai Zhang, Junjie Wang, Rui Wang, Zhe Zhou, Jie Wang, Wei Ji, Bing Ma, Boyu Ge, Yanli Wang, Zhirong Front Med (Lausanne) Medicine Hepatitis C virus (HCV)-related cirrhosis leads to a heavy global burden of disease. Clinical risk stratification in HCV-related compensated cirrhosis remains a major challenge. Here, we aim to develop a signature comprised of immune-related genes to identify patients at high risk of progression and systematically analyze immune infiltration in HCV-related early-stage cirrhosis patients. Bioinformatics analysis was applied to identify immune-related genes and construct a prognostic signature in microarray data set. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analyses were conducted with the “clusterProfiler” R package. Besides, the single sample gene set enrichment analysis (ssGSEA) was used to quantify immune-related risk term abundance. The nomogram and calibrate were set up via the integration of the risk score and clinicopathological characteristics to assess the effectiveness of the prognostic signature. Finally, three genes were identified and were adopted to build an immune-related prognostic signature for HCV-related cirrhosis patients. The signature was proved to be an independent risk element for HCV-related cirrhosis patients. In addition, according to the time-dependent receiver operating characteristic (ROC) curves, nomogram, and calibration plot, the prognostic model could precisely forecast the survival rate at the first, fifth, and tenth year. Notably, functional enrichment analyses indicated that cytokine activity, chemokine activity, leukocyte migration and chemotaxis, chemokine signaling pathway and viral protein interaction with cytokine and cytokine receptor were involved in HCV-related cirrhosis progression. Moreover, ssGSEA analyses revealed fierce immune-inflammatory response mechanisms in HCV progress. Generally, our work developed a robust prognostic signature that can accurately predict the overall survival, Child-Pugh class progression, hepatic decompensation, and hepatocellular carcinoma (HCC) for HCV-related early-stage cirrhosis patients. Functional enrichment and further immune infiltration analyses systematically elucidated potential immune response mechanisms. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326446/ /pubmed/34350203 http://dx.doi.org/10.3389/fmed.2021.716869 Text en Copyright © 2021 Guo, Dong, Zhang, Wang, Wang, Zhou, Wang, Ji, Ma, Ge and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Guo, Cheng Dong, Chenglai Zhang, Junjie Wang, Rui Wang, Zhe Zhou, Jie Wang, Wei Ji, Bing Ma, Boyu Ge, Yanli Wang, Zhirong An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title | An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title_full | An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title_fullStr | An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title_full_unstemmed | An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title_short | An Immune Signature Robustly Predicts Clinical Deterioration for Hepatitis C Virus-Related Early-Stage Cirrhosis Patients |
title_sort | immune signature robustly predicts clinical deterioration for hepatitis c virus-related early-stage cirrhosis patients |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326446/ https://www.ncbi.nlm.nih.gov/pubmed/34350203 http://dx.doi.org/10.3389/fmed.2021.716869 |
work_keys_str_mv | AT guocheng animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT dongchenglai animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT zhangjunjie animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangrui animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangzhe animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT zhoujie animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangwei animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT jibing animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT maboyu animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT geyanli animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangzhirong animmunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT guocheng immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT dongchenglai immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT zhangjunjie immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangrui immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangzhe immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT zhoujie immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangwei immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT jibing immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT maboyu immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT geyanli immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients AT wangzhirong immunesignaturerobustlypredictsclinicaldeteriorationforhepatitiscvirusrelatedearlystagecirrhosispatients |